China'sCOVID-19vaccineissafeenoughandmoreattractive_said

时间：2020-12-18 14:33:52 来源：作者：网络转载

ChinaRadio

大小：21.5M更新：2020-12-13

分类：影音播放

原标题：China's COVID-19 vaccine is safe enough and more attractive

At present, China has 5 COVID-19 vaccines entering the final clinical trial stage before marketing. Tests in more and more countries have also proved the safety of Chinese vaccines, and Chinese vaccines are more attractive in the international market.

According to the website of the Turkish newspaper "Freedom", Turkish officials said that the test results of volunteers who participated in the Chinese COVID-19 vaccine trial in Turkey did not show major side effects.

The third phase of China's COVID-19 pneumonia vaccine trial began on September 15 and is currently being conducted in two phases. These trials are being conducted among high-risk health workers and medium-risk volunteers.

The article said that so far, no obvious side effects have been reported. The most common side effects include fatigue, headache, muscle pain, and fever.

Currently, volunteers are vaccinated in 25 centers in 12 provinces of Turkey. The Chinese vaccine can be administered to people aged 18 to 59.

Turkish Health Minister Fahretin Koca previously announced that Turkey will purchase 10 million doses of the COVID-19 vaccine from China's Kexing Biological Company in December.

According to a report on the US CNBC website, Singaporean economists said that China's vaccines are more "attractive" for developing countries.

The chief economist and managing director of DBS Group Taimur Baig (Taimur Baig) said that Beijing's willingness to provide vaccines to developing countries has increased the attractiveness of China's vaccines.

Baig said that if developing countries want to obtain vaccines developed by the West, they may have to wait a long time, but they can choose to switch to China. "Considering the billions of vaccines needed and the risk of being placed behind the long line of Western vaccines, the appeal of Chinese vaccines to developing countries is obvious."

The article said that after Western vaccines are approved by regulatory agencies, countries will actively purchase, and poorer countries may find that they cannot afford such vaccines.

At present, developed countries have received a total of 85% of the total bilateral bookings for the COVID-19 vaccine. Countries such as the United States, the United Kingdom, Australia, Canada, Japan and the European Union have placed orders in excess of their populations.

China has five independently developed candidate vaccines that have entered phase III trials. This is usually the last step before the government regulator approves the vaccine.

According to the article, compared with Moderna, Pfizer and BioNTech, which use Messenger RNA technology, Chinese vaccines have another advantage: the production process of the former requires a lot of money to ensure that the vaccine is kept at extremely low temperatures. Under storage, but the Chinese vaccine does not have this problem.

Baig said that lower costs and China's willingness to provide vaccines have increased their appeal. "So (Chinese vaccine) may be cost-competitive and easier to handle in transportation."

In addition, China has signed agreements to test and produce vaccines in countries such as Indonesia, Pakistan, and Mexico.

The article said that Beijing has also joined the New Coronary Pneumonia Vaccine Implementation Plan (Covax) supported by the World Health Organization. The alliance seeks to allow all participating countries to have equal access to the vaccine after the vaccine is successfully developed. Its goal is to provide a lifeline for low-income countries, otherwise these countries will not be able to afford the COVID-19 vaccine.

[责任编辑: 张舟 ] 游戏网

资源转载网络，如有侵权联系删除。